Lipoprotein (a) increased – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 08 Sep 2026 04:56:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lipoprotein (a) increased – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a) https://clinicaltrials.eu/trial/phase-2-study-of-mk-7262-and-enlicitide-decanoate-in-adults-with-high-lipoprotein-a/ Thu, 20 Aug 2026 04:04:03 +0000 https://clinicaltrials.eu/trial/phase-2-study-of-mk-7262-and-enlicitide-decanoate-in-adults-with-high-lipoprotein-a/ The study focuses on adults who have Elevated lipoprotein(a), a blood protein that can increase the risk of heart disease. High levels of this protein, often called Lp(a), together with high LDL-C (the “bad” cholesterol) are linked to more plaque buildup in arteries.

The investigation tests a new oral medication called MK-7262 alone and in combination with a second oral agent, enlicitide decanoate. The goal is to see whether these medicines can lower the amount of the protein and the bad cholesterol more than a dummy pill (placebo).

Participants will take the assigned tablets once daily for several weeks, with regular check‑ins at the clinic to collect blood samples and report any side effects. The study lasts about two months, after which safety and how well the medicines worked are assessed.

]]> A study testing DII235 compared to placebo in adults with high lipoprotein(a) levels to reduce heart disease risk https://clinicaltrials.eu/trial/a-study-testing-dii235-compared-to-placebo-in-adults-with-high-lipoproteina-levels-to-reduce-heart-disease-risk/ Mon, 03 Aug 2026 10:41:36 +0000 https://clinicaltrials.eu/trial/a-study-testing-dii235-compared-to-placebo-in-adults-with-high-lipoproteina-levels-to-reduce-heart-disease-risk/ This study is looking at people who have high levels of a substance called lipoprotein(a) in their blood. Lipoprotein(a) is a type of fat-carrying particle that, when present in high amounts, may increase the risk of heart and blood vessel problems. The study will test a treatment called DII235, which is given as an injection under the skin. Some participants will receive DII235 while others will receive placebo. The treatment also involves sodium chloride and glucose monohydrate solutions that are used as part of the injection preparation.

The purpose of the study is to find out how well different doses of DII235 work in lowering lipoprotein(a) levels compared to placebo, and to check if the treatment is safe and well-tolerated. The study will also look at whether DII235 can reduce lipoprotein(a) levels to specific target amounts over time. People taking part in this study will have either existing heart and blood vessel disease, which means they have had problems like heart attacks, procedures to open blocked arteries, narrowing of arteries in the heart, brain, or legs, or they have Type 2 diabetes mellitus, which is a condition where the body does not properly control blood sugar levels.

During the study, participants will receive injections under the skin over a period of 18 months. The study doctors will measure lipoprotein(a) levels in the blood at different time points to see how much they change from the beginning of the study. Measurements will be taken at various times including around day 60, day 180, day 240, and day 360. The study will also track any unwanted effects, check blood test results, and monitor vital signs like blood pressure and heart rate to make sure the treatment is safe. Participants will need to continue taking their regular medications for heart health and cholesterol as prescribed by their doctor throughout the study.

]]>